Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states

被引:66
|
作者
Wen, Feng [1 ,2 ]
Zheng, Hanrui [2 ,3 ]
Zhang, Pengfei [1 ,2 ]
Liao, Weiting [1 ,2 ]
Zhou, Kexun [1 ,2 ]
Li, Qiu [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[2] Sichuan Univ, West China Biostat & Cost Benefit Anal Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Clin Pharm, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
atezolizumab and bevacizumab; cost‐ effectiveness; first‐ line systemic treatment; unresectable hepatocellular carcinoma; PRIMARY LIVER-CANCER; HEPATITIS-B-VIRUS; THERAPIES;
D O I
10.1111/liv.14795
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims In patients with unresectable hepatocellular carcinoma (HCC), the combination of atezolizumab and bevacizumab improved progression-free survival (PFS) and overall survival compared with sorafenib in the IMbrave150 trial. However, whether the price of the combination could be affordable is unknown. The current study assessed the cost-effectiveness of the combination of atezolizumab and bevacizumab as first-line systemic therapy for patients with unresectable HCC from the Chinese and American payers' perspective. Methods A Markov model was built based on a global, multicentre, open-label, phase III randomized trial (IMbrave150, NCT03434379) that included three states of the patient's health: stable disease (SD), progressive disease (PD) and death. Data for all medical costs were acquired from the Red Book, published literature and West China Hospital. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) were the primary outcomes. Sensitivity analyses were performed to evaluate the model uncertainty. Results The treatment consisting of a combination of atezolizumab and bevacizumab yielded an additional 0.53 QALYs compared with sorafenib alone, leading to an ICER of $145,546.21 per QALY in China and $168,030.21 per QALY in the USA, both beyond the willing-to-pay threshold ($28,527.00/QALY in China and $150,000.00 /QALY in the USA). The utility of the PD state was the most influential factor in the Chinese model, and the American model was the most sensitive to the price of sorafenib. The results of the models were robust across sensitivity analyses. Conclusion The combination of atezolizumab and bevacizumab was not a cost-effective strategy for the first-line systemic treatment of unresectable HCC from the Chinese and American payers' perspective.
引用
收藏
页码:1097 / 1104
页数:8
相关论文
共 50 条
  • [21] Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
    Saiyed, Masnoon
    Byrnes, Joshua
    Srivastava, Tushar
    Scuffham, Paul
    Downes, Martin
    CLINICAL DRUG INVESTIGATION, 2020, 40 (12) : 1167 - 1176
  • [22] Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
    Zou, Huimin
    Lai, Yunfeng
    Chen, Xianwen
    Ung, Carolina Oi Lam
    Hu, Hao
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
  • [23] Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
    Zheng, Zhiwei
    Lin, Yuxuan
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [24] Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study
    Liu, Lulu
    Wang, Lei
    Ding, Yiling
    Zhang, Qilin
    Shu, Yamin
    BMJ OPEN, 2025, 15 (03):
  • [25] Atezolizumab plus bevacizumab combination therapy compared to sorafenib and atezolizumab monotherapies for treatment of unresectable or metastatic hepatocellular carcinoma
    Ahmed, Faiza
    Guntipalli, Prathima
    Yukselen, Zeynep
    Coronel, Maria-Kassandra
    Zaidi, Madiha
    Onwumeh-Okwundu, Jennifer
    Garimella, Vamsi
    Gudapati, Sravya
    Mezidor, Marc-Darlene
    Andrews, Kim
    Mouchli, Mohamad
    Shahini, Endrit
    Mohan, Karthik
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 69 - 70
  • [26] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Hongyu Gong
    Siew Chin Ong
    Fan Li
    Zhiying Weng
    Keying Zhao
    Zhengyou Jiang
    Cost Effectiveness and Resource Allocation, 21
  • [27] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Gong, Hongyu
    Ong, Siew Chin
    Li, Fan
    Weng, Zhiying
    Zhao, Keying
    Jiang, Zhengyou
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [28] Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
    Kobayashi, Kojiro
    Nagai, Hidenari
    Matsui, Teppei
    Matsuda, Takahisa
    Higai, Koji
    ANTICANCER RESEARCH, 2023, 43 (10) : 4601 - 4609
  • [29] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
    Masahiro Kobayashi
    Masatoshi Kudo
    Namiki Izumi
    Shuichi Kaneko
    Mie Azuma
    Ronda Copher
    Genevieve Meier
    Janice Pan
    Mika Ishii
    Shunya Ikeda
    Journal of Gastroenterology, 2019, 54 : 558 - 570
  • [30] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
    Kobayashi, Masahiro
    Kudo, Masatoshi
    Izumi, Namiki
    Kaneko, Shuichi
    Azuma, Mie
    Copher, Ronda
    Meier, Genevieve
    Pan, Janice
    Ishii, Mika
    Ikeda, Shunya
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (06) : 558 - 570